Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pucotenlimab with Gemcitabine and Cisplatin for Pediatric LELC
NCT06969534Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- May 2025
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pucotenlimab in lymphoepithelioma-like carcinoma (LELC), sponsored by Sun Yat-sen University. Primary endpoint: Progression-Free Survival at 24 months. Started May 2025; status: recruiting.
02
Drugs
pucotenlimab
03
Conditions
lymphoepithelioma-like carcinoma (LELC)
Beyond the preview
Go deeper on NCT06969534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06969534.